Corporate Member Update: Merck

Corporate Member Update: Merck

WELIREG® (belzutifan)
February, 2024

Merck would like to inform you that the FDA has approved WELIREG® (belzutifan) 40-mg tablets for the treatment of adult patients with advanced renal cell carcinoma (RCC) following a programmed death receptor-1 (PD-1) or programmed death ligand 1 (PD-L1) inhibitor and a vascular endothelial growth factor tyrosine kinase inhibitor (VEGF-TKI).

To read the full press release, please click here!

Become a NOS Member Today!

Platinum Corporate Members

Gold Corporate Members